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INTRODUCTION 
Individuals experience disease and respond to treatment differently. 1 Accordingly, 
medical practitioners currently follow a trial-and-error approach when treating patients.2 
In other words, if a patient has a disease, his or her doctor will prescribe a treatment plan 
based on general information and re-assess after a few weeks.3 If the treatment is not 
working, the doctor will change some variable in the plan, and wait a few more weeks 
to see if there is any improvement.4 This approach can lead to patient dissatisfaction, 
adverse drug responses and drug interactions, and poor adherence to treatment 
regimens. 5 While this may seem bleak, rapid developments in a variety of medical fields 
like genomics, medical imaging, and computational biology are making it possible for 
scientists and doctors to personalize diagnosis and treatment of diseases.6 Thus, the 
practice of medicine is becoming more personalized. The term "personalized medicine" 
is often described as providing "the right patient with the right drug at the right dose 
at the right time."7 The Food & Drug Administration (FDA) describes personalized 
medicine as "the tailoring of medical treatment to the individual characteristics, needs 
and preferences of a patient during all stages of care, including prevention, diagnosis, 
treatment and follow-up."8 
Personalized medicine usually involves the use of two medical products to improve 
patient outcomes.9 These products may be diagnostic devices, therapeutic drugs, or 
biological products. 10 A diagnostic device is a medical device that is used to identify the 
presence, absence, or amount of a biomarker (as in the case of in vitro diagnostics) or 
to assess physiological or anatomical patient characteristics. 11 "Companion" diagnostic 
devices are becoming increasingly important to the development of drugs. Companion 
1 FDA, Paving the FDA s Role in a New Era 
ueveumm1ent 5-6 (2013), http://W\vw.fda.gov/downloads/ScienceResearch/SpecialTopics/ 
PersonalizedMedicine/U CM3 72421. pdf. 
2 Id. at 6. 
Id. 
4 Id. 
5 Id. While there are some benefits to the trial-and-error approach, this approach is unable to 
diagnose a disease at its outset, lengthening the amount of time before a disease is either 
cured or manageable. This identifies what is most to be the disease, and then 
experiments with treatments until one works. Precision medicine offers a more exact 
and characteristics of 
6 Id.; see also MA.Yo CLINIC, Consumer Health: Personalized Medicine 
(Jul. 14, 2012), http://www.mayoclinic.org/healthy-living/ consumer-health/in-depth/personalized-
medicine/ ari-20044300 (describing how to use trial and error to find the best treatment for a 
particular patient). 
FDA, Paving the supra note 1 at 6. 
8 Id. 
9 Id. at2. 
10 Id. 
11 Id. at 10; see also Strimbu and Jorge A. Tave!, T¥hatAre Biomarkers?, CuRR. 0PIN. HIV 
AIDS 463-66 (2010) ( descr1bn1g the potential for biomarkers to speed development and reduce 
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diagnostics are usually in vitro medical devices that provide information necessary for 
"the safe and effective use of a corresponding drug or biological product." 12 These help 
health care providers determine the risks and benefits of a particular drug for a patient. 13 
Specifically, companion diagnostics can: 1) identify patients who will most likely 
benefit from a particular drug; 2) identify patients who will likely be at an increased 
risk for serious side effects from a drug; and 3) monitor patient responses to treatments 
with a drug to adjust treatment to achieve improved safety or efficacy. Companies are 
developing companion diagnostics for use in earlier stages of drug development and are 
co-developing drugs and companion diagnostic tests. 14 
In addition to companion diagnostics, the FDA states that combination products also fall 
under the personalized medicine umbrella. 15 Combination products are becoming more 
prevalent and important in treating patients. Combination products are diagnostic and 
therapeutic medical products that combine biological products, drugs, and/or devices 
because several are necessary to achieve the indication. 16 Some examples of approved 
combination products are drug-eluting stents for clogged heart arteries, surgical mesh 
with antibiotic coating, and drug patches used to treat depression. 17 These innovative 
combination products improve on previous products by using new and more tailored 
methods to treat disease quickly and effectively. 
These tailored methods are potentially more effective at preventing and treating diseases, 
therefore easing patients' burdens. For instance, by improving the ability to predict 
and account for individual differences in disease diagnosis, experience, and therapy 
response, personalized medicine can diminish the severity of disease, shorten product 
development timelines, and improve success rates. 18 With the help of personalized 
medicine, health care management can focus more on wellness and maintaining health, 
rather than on illness and treating disease. 19 Furthermore, personalized medicine can 
reduce healthcare costs by improving the ability to reliably select effective therapy for 
a patient while minimizing the costs of ineffective treatments and the risk of avoidable 
adverse events.20 
The FDA plays a crucial role in the future of personalized medicine. The FDA has specific 
and distinct regulatory pathways for devices, drugs, and biologics. This paper will focus 
13 Id. 
14 Dan Ressler, and Glem1 
Diagnostics, 8 PHARMACOGENOMlCS AND PERSONALIZED MEDICINE 99 (2015) 
for and the various ways can them under cmrent 
and economic obstacles). 
ls FDA, Paving the 
20 Id. 
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on combination products and companion diagnostics and how the FDA regulates them. 
Part II of this paper will introduce the process that combination products must go through 
to be allowed on the market, and the FDA's regulatory role in that process. Part III of this 
paper will analyze the current regulatory regime for companion diagnostics. Part IV will 
then recommend that the FDA use its experience from regulating combination products 
and apply a similar regulatory regime for companion diagnostics. Specifically, this paper 
will recommend that the FDA create an Office of Companion Diagnostics because 
it will help organize and clarify how companion diagnostics and their corresponding 
therapeutic products are regulated, and will centralize the necessary expertise to assist 
in approving these products. With the growth of companion diagnostics, the drug and 
device regulatory regimes will become more intertwined and interconnected, and this 
office will help address issues associated with this growing merger. Finally, this paper 
will conclude by explaining how an Office of Companion Diagnostics will advance 
personalized medicine by clarifying the regulatory process so industry can focus on the 
development of companion diagnostics. 
I. COMBINATION PRODUCTS 
A. History 
Because combination products combine components of biological products, drugs, 
and/or devices, they involve components that would traditionally be regulated 
under different types of regulatory authorities and different FDA Centers. 21 These 
centers include the Center for Biologics Evaluation and Research (CBER), the 
Center for Drug Evaluation and Research (CDER), and the Center for Devices and 
Radiological Health (CDRH). 22 There are three categories of combination products: 
1) single-entity combination products (e.g. prefilled syringes, drug-eluting stents); 
2) co-packaged combination products (e.g. first aid kits, surgical procedure kits); 
and 3) cross-labeled combination products (e.g. a drug and a laser that activates 
it). 23 These products raise regulatory, policy, and review management challenges. 24 
Individually, drugs and devices have very distinct regulatory pathways with differing 
requirements. 25 Drugs must meet stricter safety and efficacy standards, as they 
achieve their primary purpose by affecting a structure or function of the body. 26 
Devices, on the other hand, do not use chemical action either on or within the body 
21 FDA, About Combination Products, 
AboutCombinationProducts/default.htm. 
22 Id. 
FDA, Questions about Combination Products, 
Com binationProducts/ About CombinationProducts/ucm 101496.htm 
24 Id 
25 Lewis A. Grossman, Drugs, and Devices: FDA Intellectual 
Property, and lvfedical Products in the Health Care System, in THE OXFORD HANDBOOK 
OF US. HEALTHCARE (L Glenn Cohen et aL ed., 2015) the law icuvcrn.m" 
Llrnrn"'~"• and devices). 
26 Id 
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to achieve their intended purpose. 27 Therefore, the statutory requirements for device 
marketing approval applications are slightly easier to meet. 28 
These differences in regulatory pathways for each component of a combination product 
can affect all aspects of product development, including pre-clinical testing, clinical 
investigation, marketing applications29 , manufacturing and quality control, adverse 
event reporting, promotion and advertising30, and post-approval modifications31 .32 
In 2002, Congress passed the Medical Device User Fee and Modernization Act 
(MDUFMA), which required FDA to establish the Office of Combination Products 
(OCP) and gave the office broad responsibilities covering the regulatory life cycle 
of drug-device, drug-biologic, and device-biologic combination products. 33 Congress 
made this requirement because of the challenges of combination products from patient, 
medical, and legal perspectives. 34 
On December 24, 2002, FDA established OCP and gave it several responsibilities.35 
First, OCP serves as a focal point for combination product issues for agency reviewers 
and industry.36 Second, OCP develops guidance and regulations to clarify the regulation 
of combination products.37 Third, OCP assigns an FDA center to have primary 
jurisdiction for review of both combination and single entity (i.e., non-combination) 
products where the jurisdiction is unclear or in dispute.38 Fourth, OCP ensures timely 
and effective premarket review of combination products by overseeing the timeliness 
of and coordinating reviews involving more than one agency center.39 Fifth, OCP 
ensures consistency and appropriateness of post-market regulation of combination 
products.40 Sixth, OCP resolves disputes regarding the timeliness of premarket review of 
27 Id. 
28 Id. (explaining the differing regulatory requirements for drugs and devices in further detail). 
29 See FDA, Questions about Combination Products, supra note 23 (explaining 
that the Office of Combination reviews marketing from companies who have developed 
a product and want FDA approval so can then legally sell their product to consumers). 
30 The FDA regulates how companies can promote and advertise their to consumers. The 
FDA does this to make sure that companies are truthful and don't mislead consmners. 
31 After a product is sometimes new information has been learned and companies 
sometimes mu st modify their product. If this occurs, the FDA has certain steps for companies to 
follow to properly modify their products. 
32 Id. 
33 FDA, Summary Medical Device User Fee and Modernization Act 
http://v.T\vw.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/ 
MedicalDeviceU serFeeandModemizationActMDUFMA/ucm 109 l 05 .htm. 
34 FDA, Transcript Hearing on FDA Products, 
f da.gov/downloads/CombinationProducts/MeetingsConferences Workshops/U CM 117123. pdf. 
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combination products.41 Seventh, OCP updates agreements, guidance documents, and 
practices specific to the assignment of combination products.42 Finally, OCP submits 
annual reports to Congress on the Office's activities and impacts.43 
B.Assignment 
When OCP receives a submission for a combination product to be commercially available 
in the United States, it designates a center with the primary regulatory responsibility 
(the "lead")."44 OCP's decision is based on whether the combination product's "primary 
mode of action" is as a (1) biologic, (2) device, or (3) drug.45 "Primary mode of action" 
(hereinafter referred to as "PMOA") is not defined by statute; the FDA promulgated 
regulations in 2005 to define the term and address how to determine the PMOA of 
a combination product.46 The FDA defines PMOA as the "single mode of action of 
a combination product that provides the most important therapeutic action of the 
combination product."47 The agency defines the most important therapeutic action as 
the combination product's "mode of action expected to make the greatest contribution 
to the overall intended therapeutic effects."48 It defines "therapeutic" effect or action to 
include any effect or action that is "intended to diagnose, cure, mitigate, treat, or prevent 
disease, or affect the structure or any function of the body."49 Therefore, CBER would 
likely have the lead for a combination product if it has a biologic PMOA; CDRH if it has 
a device PMOA; and CDER ifit has a drug PMOA.50 
The FDA determines the PMOA by looking at previously approved products or through 
case-by-case analysis.51 For some types of combination products, the constituent part 
that contributes the PMOA is well established.52 For example, ifthe combination product 
consists of a drug and a device and the device only delivers the drug but does not contribute 
to the therapeutic effect, the Agency will consistently state that this product's drug is its 
PMOA.53 To illustrate, a drug in a prefilled syringe would be considered to provide the 
PMOA.54 However, some products require case-by-case analysis because the PMOA can 
vary among similar combination products. For instance, one drug-device combination 




44 See Weiner, supra note 16 at 364. 
4s Id. 








note 16 at 364. 
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Combination Product, 70 Fed. Reg. 49,848 
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than is included in another combination product with the same intended use. 55 The device 
may provide the PMOA in the combination product that has the weaker drug, while the 
drug might provide the PMOA in the combination product that includes the stronger 
drug.56 Similarly, two combination products that include the same or similar drug and 
device constituents may have different indications, and the respective contributions of 
those constituent parts may differ depending on the indication.57 If possible, the FDA 
determines the PMOA if, with reasonable certainty, it can determine which constituent 
part appears to contribute the most to the product's intended therapeutic effects.58 In 
some cases, however, where there is not sufficient data available, the FDA uses a two-
step algorithm to determine the PMOA and the lead center for the combination product. 59 
The first step is to see whether one of the centers is already regulating a combination 
product that raises similar questions of safety and efficacy. 60 If so, the product is assigned 
to that center.61 If not, the second step is to determine which center has the greatest 
expertise with respect to the most significant questions of safety and efficacy raised 
by the combination product, and that center will be the lead.62 In some circumstances, 
as discussed below, a sponsor may also request a classification or assignment of 
their product. 
C. Request for Designation 
If the assignment of a center might be unclear, a sponsor of a combination product 
may submit a request for designation (RFD) to the OCP for a formal determination.63 
An RFD requests a determination of which FDA center will have primary jurisdiction 
for premarket review and regulation of a combination product.64 A product's sponsor 
must submit an RFD before filing any investigational or marketing application for 
the product.65 A RFD includes (1) the identity of the sponsor; (2) a description of the 
55 Id. at 364-65. 
56 Id. at 365. 
st Id. 
58 cA1J1aJ1uc•-<. "In general, it would be to determine the PMOA of a 
with 'reasonable when the PMOA is not in doubt among 
J\..lt1Jw1cu1~carnc experts, and can be resolved to an acceptable level in the minds of those experts 
based on the data and information available to the FDA at the time an is made." See 
lvlode Combination Product, supra note 46. 
s9 Id. 
60 Id.; see also 21 U.S.C.A. § 321(p) (2009) {de:h:nmga new drug and ex1Jlmnn1gthat 
efficacy are determined. by experts qualified scientific training and "v''""''"rn'" 
61 Weiner, supra note 16 at 365. 
62 Id. 
63 21 C.F.R. § (2009); see also FDA, RFD Process, nu1J:11w"rw.ma.gov1 
and. 
CombinationProducts/RFDProcess/, 4, 15, 2010). A RFD is not necessary for 
every product. It is recommended when the classification of a product or the FDA center to which it 
should be is unclear or in dispute. 
64 FDA, How ta Write a Designation 3 (2011), http:// 
\¥WW.f <la.gov/ dmll/llloads/RegulatoryJnformation/Guidances/lJ CM25 l 544.pdf. 
65 Id. at 4. 
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product66; and (3) the sponsor's recommendation as to which Agency center should 
have primary jurisdiction.67 Within 5 days of receiving a RFD, OCP must review the 
submission for completeness and determine whether the RFD contains the required 
information.68 OCP must then either send the sponsor an acknowledgement letter 
confuming the filing date of the RFD or notify the sponsor that the RFD was not filed 
and specify what information is necessary to complete the filing of the RFD. 69 If OCP 
does not issue a designation letter within 60 calendar days of the filing of the RFD, 
as required by 21 CFR 3.8(b), the sponsor's recommendation for the classification or 
assignment of the product will become the designated classification or assignment.70 
If a product sponsor disagrees with the OCP's jurisdictional determination, the sponsor 
can request reconsideration of a decision within 15 calendar days of receipt of the 
designation letter. 71 A request for reconsideration cannot exceed 5 pages and cannot 
include any new information that was not contained in the original RFD.72 The FDA 
must then review and give a response to the sponsor within 15 calendar days of receipt 
of the request for reconsideration.73 If the sponsor wishes to submit additional or new 
data, the sponsor must submit a new RFD containing that information, and the OCP will 
consider that RFD a new submission.74 It is important to note, however, that the letter 
of designation issued by the FDA is a binding determination that can only be modified 
under the conditions outlined in Section 563 of the FD&C Act and 21 CFR 3.9.75 
D. Regulatory Issues 
1. Premarket Regulation: Marketing Authorization Requirements and Processes 
A variety of issues arise during the premarket regulation process of combination 
products. The marketing authorization pathways, regulatory standards, and procedures 
for combination products are those for drugs, devices, and biological products. 76 
However, these pathways, standards, and procedures, having been designed for one 
type of product, are not always properly applicable to a combination of products. The 
main issues for combination products concern how to ensure that all of the regulatory 
should include: (a) classification, 
is marketed as not 
rnv"'""''"'v"'" exemption, (e) chemical, 
status and of the results work, (g) rlP<:rnntu>n 
processes, rlPc'r•·•·ntum of all known modes of action, (j) schedule 
and duration of use, dose and route of administration 
related and (m) any other relevant information). 
67 Id. at 6-7; see also 21C.F.R.§3.7(c)(2015). 
68 § 3.8(a). 
69 FDA, 
70 Id. 




75 Id. at 3-4. 
76 Weiner, supra note 16 at 367. 
How to Write 
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or (I) of 
Designation supra note 64 at 5. 
Designation supra note 69 at 5. 
9 
issues raised by a combination product are appropriately addressed, regardless of the 
regulatory pathway by which it may enter the FDA.77 The PMOA standard determines 
which center will have the lead for regulation of a combination product, however, it 
does not clear up what types of investigational and marketing authorization submissions 
should be pursued for the approval of the product. 78 It also does not expressly address 
what review standards or data requirements should apply for combination products or 
whether these standards should vary upon which center has the lead. 79 Furthermore, 
the PMOA standard does not establish how the lead and non-lead centers should 
coordinate or how sponsors should interact with either. 80 However, statutory language 
and agency policies, statements, and practice offer insight into these questions. 81 
Combination products also pose questions regarding what information is necessary on 
their investigational applications. 
2. Investigational and Marketing Submissions 
The FDA only requires one investigational application for a combination product, but 
a combination product may require more than one marketing application. 82 However, 
CDER, CBER, and CDRH do not currently have the delegated authority to review all 
marketing application types. 83 Specifically, CDER has the authority to review some 
biologics licensing applications (BLAs ), 84 new drug applications (ND As), abbreviated 
NDAs (ANDAs), and investigational new drug applications (INDs). 85 CDRH has the 
authority to review Premarket Approvals (PMAs), 510(k)s86, Humanitarian Device 
Exceptions (HDEs), and Investigational Device Exemptions (IDEs). 87 Finally, CBER 
has the authority to review all of these types of submissions. 88 While the FDA has not 
77 Id. 
78 Id. at 367-68. 
79 Id. 
80 Id. at 368. 
81 Weiner, supra note 16 at 368. 
82 FDA, Questions about Combination Products, supra note 23. 
83 Weiner, supra note 16 at 368. 
84 CDER and CBER both have regulatory responsibility over therapeutic biological products. 
The categories of therapeutic biological products that CDER regulates are: monoclonal antibodies 
for in vivo use, most proteins intended for therapeutic use, and immunomodulators. See FDA, 
Questions about I h1>rn•nP1.1t1r nl<Jto)'!;Wat Prnr;rurts 
DevelopmentApprovalProcess/%20HowDrugsareDevelopedandApproved/ApprovalApplications/ 
TherapeuticBiologicApplications/ucml 13522.htm, updated Dec. 15, 2014). 
85 Weiner, supra note 16 at 368. 
86 A is a premarket notification a device company to the FDA notifying that the company 
intends to market a device that is equivalent to another medical device that is on the market. 
Essentially, its not a "new" device, and can be more classified by the FDA rather than a new 
device that would more information. See FDA, Clearances, nmJ:11wv./\V.ma.2o>v1 
MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/51 OkClearances/ 
(last Jan. 26, 2016). 
87 Weiner, supra note 16 at 368. 
88 Id. 
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stated that the submission types associated with the constituent part that provides the 
PMOA must or may always be used, they usually are. 89 
There are key questions to consider in evaluating what investigational and marketing 
authorization submissions to make for combination products. First, which constituent 
part provides the PMOA?90 Second, which submissions type(s) associated with that 
constituent part is (are) available forthe combination product?91 Usually, the FDA requires 
only one marketing application per combination product, particularly if its constituent 
parts are physically or chemically combined into one product.92 However, if the FDA 
permits or requires a marketing authorization for each constituent part, each would be 
of a type normally associated with that kind of product (e.g. an NDA or ANDA for a 
drug constituent part; a PMA or 51 O(k) for a device constituent part).93 Each submission 
would be made to the center normally responsible for that type of product (e.g. an NDA 
would be submitted to CDER and a PMA would be submitted to CDRH).94 According 
to the FDA, the centers still coordinate on the review of the product even though each 
center would receive its own submission to review. 95 The FDA has noted that some of 
the same data could be presented and relied upon for both marketing authorizations.96 
While the formal submission type may have limited significance for the data needed to 
support marketing authorization for a combination product, the type of submission(s) 
available could have other implications relevant to business judgments and product 
development planning. 97 For example, there is a remarkable difference in user fees for 
marketing submissions, even though waivers and reduced fees may be available.98 User 
fees allow the FDA to collect payments from companies and these fees help the FDA 
expedite approval processes.99 Standard fees for NDAs currently range from about $1 
million to $2 million, for PMAs being about $250,000, for ANDAs being over $50,000, 
and for 51 O(k)s being nearly $5,000. 10° Combination products that are reviewed under a 
single marketing authorization should be subject to the fee associated with that type of 
authorization. 101 If two authorizations are necessary, then the fee associated with each 
applies to the combination product. 102 
89 Id. 
90 ld. at 361. 
91 Id. at 368. 
92 Suzanne O'Shea, 
(2008). 




97 Id. at 368-69. 
98 
99 
the Combination Products, RAJ PHARMA 653 
S. 




note 16 at 369. 
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Additionally, some marketing submission types offer protections from competition, 
while others do not. For example, the provisions for marketing a product under a NDA 
or BLA protect patent rights and grant periods of marketing exclusivity during which the 
FDA cannot approve follow-on products that seek to rely on the FDA's prior approval of 
the same or a similar product. 103 However, abbreviated marketing authorizations would 
be available to allow follow-on applicants to be on the market once such exclusivities 
expire. 104 In contrast, if a product is marketed under a 51 O(k), no marketing exclusivity 
applies, so a follow-on product could be cleared at any time. 105 Finally, if a product is 
marketed under a PMA, there is a six-year data exclusivity provision. 106 Aside from 
regulatory pathways and marketing applications, combination products must also meet 
substantive requirements. 
3. Standards for Marketing Authorization 
While the FDA has not published general guidance on what substantive requirements 
must be met to obtain marketing authorization for a combination product, it has stated 
that each constituent part of a combination product retains its legal status as a drug, 
device, or biologic. 107 In specific guidance for products, the FDA has indicated that 
considerations raised by each constituent part will be addressed in keeping with standard 
approaches for such products. 108 For example, considerations normally reviewed for an 
injector marketed under a device pathway would also be considered for an injector being 
reviewed under a NDA or BLA. 109 The FDA has also indicated a marketing authorization 
for a combination product must address questions associated with each of its constituent 
parts, as if each part were marketed independently. no Furthermore, the FDA has 
indicated that a marketing authorization must also consider questions of safety and 
efficacy that arise when constituent parts are combined. 111 To meet these requirements, 
experts from several offices must work together to evaluate the combination product. 
103 See 21 C.FR. § 314.108 (2015) 
promote a balance between a new 
104 Id. 
105 Weiner, supra note 16 at 369. 
106 
1 vAprnurn,10 that any infom1ation contained in an aµ~mc;21.ulm for 
available for six years). 
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4. Inter-Center Coordination and Sponsor-FDA Interaction For Premarket Review of 
Combination Products 
The FDA has established standard operating procedures (SOPs) and mechanisms to 
facilitate inter-center coordination, agency-sponsor interaction, and coordination 
between sponsors and third parties. 112 Combination products often require complex 
inter-center coordination and interaction in order to facilitate premarket review. 113 
Premarket review systems for combination products provide for coordination between 
the lead center and the center(s) that typically regulate the other constituent part(s) 
included in the combination product. 114 For example, the FDA has an SOP that includes 
a formalized process for enabling the lead center to seek input from the secondary 
center(s). 115 OCP sends annual reports to Congress and these include data tracking of 
the number of consults between centers. 116 
Sponsors coordinate with the FDA through the lead center. 117 A product's sponsor can 
work with the lead center to confirm that other centers, offices, and staff are participating 
in meetings and reviewing the sponsor's submission in a timely manner. 118 OCP 
facilitates scheduling of meetings and coordinates other matters between the sponsor 
and the FDA. 119 Furthermore, OCP helps resolve disputes regarding product review. 120 
Good relationships between sponsors and manufacturers of different types of products 
can further support product review and the approval process. 121 For example, if a drug 
sponsor and a device manufacturer are developing a product together, their relationship 
can benefit the approval process. 122 If they have a good relationship, they will be 
better equipped to work together and address any concerns the FDA centers may have. 
Furthermore, if a device manufacturer already has an approved independent product that 
is similar to the one they are developing with a drug sponsor, the device manufacturer 
can allow the FDA to access the data for the already approved device. 123 If the FDA can 
look at a previous approval and the data and information associated with that approval, 
the FDA's decision process for a new product that is similar will be easier and likely 
expedited. Once a combination product is approved, OCP's role does not end. 
112 Weiner, supra note 16 at 370. 
113 
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E. Post-Market Regulation 
The OCP's responsibilities include ensuring consistent and appropriate post-market 
regulation of combination products. 124 To that end, OCP has issued a final rule on 
current good manufacturing practices (cGMPs), a proposed rule on post-marketing 
safety reporting (PSR) for combination products, and a final rule on unique identification 
for devices. 125 With each of these, OCP has worked to streamline compliance with 
regulatory requirements while simultaneously ensuring that sponsors demonstrate the 
safety and effectiveness of combination products. 126 When OCP developed the cGMP 
and PSR rules for combination products, OCP worked with expert staff from the 
various centers to review the applicable regulations for drugs, devices, and biological 
products. 127 OCP aimed to ensure that these regulatory requirements were met and to 
minimize any unnecessary overlap. 128 
Combination products require coordination across centers and other agency offices 
during post-market regulatory activity. 129 The different Centers and the Office of 
Regulatory Affairs can work together on manufacturing facility inspection activities 
and on evaluation and response to post-market safety reports. 130 OCP assists in that 
coordination so that combination products are in compliance with all regulatory 
requirements and can maintain their presence on the market. 131 
F. Disputes over the OCP's Center Assignment 
Generally, OCP has worked well with combination product sponsors; however, one 
case, Prevor v. FDA, 132 has garnered a great deal of attention and has highlighted 
several issues associated with combination products. After developing its drug-device 
combination product, Diphoterine Skin Wash (DSW), Prevor requested that the FDA 
assign CDRH as its lead center. 133 Prevor argued that the product's PMOA came from its 
device constituent part. 134 However, the FDA stated that DSW had a drug PMOA, and 
Prevor challenged this determination. 135 
125 Weiner, supra note l 6 at 372. 
126 Id 
127 Id 
128 Id. OCP has been successful in its endeavors and has not had many However, 
there have been some, which will be discussed later on in this article. 
129 Id. at 372-73. 
130 Id 
131 Id at 373. 
132 895 F Supp. 2d 90 (D.D.C. 2012) that the FDA failed to articulate it loosened 
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In its challenge, Prevor focused on the original intention ofDSW. Prevor created DSW 
to mitigate chemical burns. 136 It is a liquid substance that is contained in a canister 
propelled by pressurized gas. 137 The liquid substance is colorless and odorless and is 96% 
water and 4% diphoterine. 138 Prevor claimed that the "first use is a physical/mechanical 
mode of action (comprises approximately 90% of DSW's overall effect), while the 
second one is a chemical mode of action (comprises 10% ofDSW's overall effect)."139 
The FDA stated that if the product depends "at least in part" on any chemical action, 
then it is automatically not a device. 140 Prevor countered this argument claiming that 
OCP erred by "contradicting established agency precedents, disregarding information 
provided in the RFD, and applying a novel review standard not found in or supported 
by law or regulation."141 Specifically, Prevor claimed that the FDA incorrectly applied 
the FDCA's definition of a device. 142 According to the statute, a product is not a device 
if it "achieves its primary intended purposes through chemical action within or on the 
body of man."143 Prevor disagreed with the FDA's conclusion that DSW has more than 
one primary intended purpose. 144 Specifically, Prevor stated that the neutralization of 
chemicals is not one ofDSW's primary intended purposes. 145 
The district court agreed with Prevor and said that the FDA's interpretation improperly 
allowed "at least in part" or "even in part" to expand the meaning of"primary."146 The 
court stated that (1) the FDA treated any purpose ofDSW as a primary intended purpose, 
and (2) the FDA treated achievement even in part of any purpose through chemical 
action as achievement of a primary intended purpose through chemical action. 147 The 
court remanded the case to allow the agency to make a determination consistent with 
the holdings in its opinion. 148 
On remand, the FDA reached the same conclusion that DSW was a drug, yet with 
one difference. 149 The FDA found that DSW had only one primary purpose: "to help 
prevent and minimize accidental chemical bum injuries."150 Prevor argued against a 
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second remand back to the FDA. 151 Instead, Prevor asked the court to classify DSW as a 
medical device or as a combination product with a medical device as the primary mode 
of action. 152 Prevor and the FDA both filed Motions for Summary Judgment. 153 
On September 9, 2014, the U.S. District Court for the District of Columbia rejected 
Prevor's argument and denied the FDA's motion. 154 The court held that in selecting one 
primary purpose alone, the FDA conveniently avoided distinguishing between primary 
and secondary purposes. 155 Furthermore, the court referred to the statute saying that 
a product does not meet the device definition if it "achieves its primary intended 
purposes through chemical action within or on the body."156 The court implied that 
the FDA's definition of "achieve" as "chemical action [that] meaningfully contributes 
to its primary intended purpose" was creative. 157 Unlike the FDA, the court did not 
find that "achieve" means "meaningfully contribute."158 In ruling against the FDA, the 
court emphasized, "Chemical action that helps or plays a significant part in bringing 
about a specific result is more than de minimis involvement, but it does not fulfill the 
congressional directive that the chemical action must achieve, i.e., accomplish or attain, 
the primary purpose."159 Furthermore, the court held that the FDA's "meaningfully 
contribute" language appeared to be a "significant shift" in the agency's practices when 
classifying products. 160 The court noted that this language does not appear in legislative 
history, any FDA guidelines, or in any other classification decisions. 161 While the FDA 
is allowed to adopt new approaches, it must offer a reasonable analysis for its new 
approach. 162 In this case, the FDA did not offer such analysis and the court stated that 
"an agency interpretation of a relevant provision which conflicts with the agency's earlier 
interpretation is 'entitled to considerably less deference' than a consistently held agency 
view."163 The court acknowledged that agency determinations are usually regarded with 
deference, particularly one such as this where the FDA has made a scientific finding 
in its area of expertise. 164 Moreover, the court recognized that on remand, the FDA 
could again find a drug primary mode of action as long as it also adopts a "plausible 
151 Id. at 139 
would 
152 Id. at 139. 
153 Id. at 128. 
reviewed the record for a second time, and 
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construction of the relevant statutory language."165 However, the court found that the 
record showed that FDA's classification decision was based on an "erroneous and 
unreasonable interpretation of the law."166 For these reasons, the court remanded the 
case back to the FDA for further proceedings consistent with its opinion. 167 
This case highlighted critical gaps in the regulation of combination products. First, the 
FDA's interpretation of"primary" in the PMOA standard was vague because PMOA has 
not been statutorily defined. While OCP has been able to work through most disputes 
or disagreements, Prevor demonstrated that the industry may benefit from further 
insight into the FDA's thought process in interpreting a PMOA. 168 Second, the FDA's 
interpretation of chemical action under Section 20l(h) of FDCA is unclear and also 
warrants further insight. 169 Still, despite the potential benefits of more guidance, the 
industry already benefits from the OCP. 
G. Benefits of OCP 
Despite Prevor, OCP has evidently been a success. For an office that holds such an 
incredible amount of responsibility, it has had very few disputes. Furthermore, industry 
describes the OCP as a "blessing."170 The Combination Products Coalition (CPC)171 
states that since its establishment, the OCP has served as an important resource to 
manufacturers. 172 CPC states that OCP "consistently helps manufacturers navigate 
the murky and sometimes stormy waters created by the cross-center regulation of their 
products."173 Most notably, CPC praises OCP for "get[ ting] some of the highest marks of 
any office at FDA when it comes to responding quickly to pleas for help."174 CPC further 
recognizes OCP's role in developing guidance documents regarding the development of 
combination products and believes OCP to be an "extremely valuable resource."175 CPC 
acknowledges that there are areas where OCP can improve, but it is happy that OCP is at 
the FDA to manage issues regarding combination products. 176 CPC has stated that OCP 
can improve by: 1) clarifying the roles and responsibilities of OCP vis-a-vis the various 
centers; 2) updating the intercenter agreements; 3) developing guidance on human 
16s Id. 
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factors and usability testing for combination products; 4) tackling the unique issues 
associated with conducting clinical trials on combination products; and 5) enhancing 
transparency through publication of Request for Designation letters. While OCP can 
improve in some ways, it has overall been a positive development. 177 CPC remembers 
the regulation of combination products before OCP existed and believes the industry is 
"lucky" to have OCP. 178 As combination products have benefited from OCP, companion 
diagnostics could benefit from a comparable office. 
H. Companion Diagnostics 
As stated earlier, companion diagnostics are medical devices, often in vitro devices, 
which provide information that is essential for safe and effective use of a corresponding 
drug or biologic. 179 The devices test to see whether a drug or biologic 's benefits outweigh 
its risks for a particular patient. 180 The area of companion diagnostics began when the 
FDA approved Herceptin, a cancer drug that shuts off a protein present in abnormally 
high amounts in about one-quarter to one-third of aggressive breast cancers. 181 The 
companion diagnostic test looks for excessive levels or extra copies of the protein HER2 
in a patient's tumor, because this indicates that Herceptin could be an effective treatment 
for that patient. 182 At the time of this article's publication, only about twenty companion 
diagnostics have been approved. 183 These new technologies are making it increasingly 
possible to individualize, or personalize, medical therapy. 
Currently, there is no Office of Companion Diagnostics atthe FDA, butthere is an Office of 
In Vitro Diagnostics and Radiological Health (OIR). 184 OIR is comprised of the Office of 
the Director, which includes the personalized medicine staff and seven divisions. 185 This 
office handles several tasks including: 1) regulating in home and laboratory diagnostic 
tests, 2) regulating radiological medical devices, 3) regulating radiation-emitting non-
medical products, and 4) implementing the Mammography Quality Program authorized 
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OIR combines pre-market and post-market responsibilities into one multi-disciplinary 
office. 187 Additionally, OIR administers the federal Clinical Laboratory Improvement 
Amendments (CLIA). 188 This can be a tremendous undertaking because it can be unclear 
as to which division handles companion diagnostics, particularly because companion 
diagnostics fall under the expertise of so many of these divisions. Compounding this 
problem is the fact that the regulatory regime for companion diagnostics is murky. 
Furthermore, there is no office that links CDRH to either CBER or CDER when 
regulatory issues regarding companion diagnostics arise. As discussed below, the FDA 
issued guidance for industry and FDA staff for in vitro companion diagnostic devices on 
August 6, 2014, but failed to resolve certain questions. 189 
I. Guidance for In Vitro Companion Diagnostic Devices 
The guidance issued by the FDA for in vitro companion diagnostic devices helped the 
industry, but left many unanswered questions. 190 The guidance assisted ( 1) sponsors 
planning to develop a therapeutic product requiring the use of an in vitro companion 
diagnostic device for the therapeutic product's safe and effective use, and (2) sponsors 
planning to develop an in vitro companion diagnostic device intended to be used with 
a corresponding therapeutic product. 191 The guidance addressed several concerns 
associated with in vitro companion diagnostic products. Specifically, inadequate 
performance of a companion diagnostic could lead to withholding appropriate 
therapy, or administering inappropriate therapy. 192 Therefore, to address the remaining 
questions regarding safety and effectiveness of both companion diagnostics and 
their complementary therapeutic product, the FDA assesses these products through 
premarket review and clearance. 193 In the guidance document, the FDA stated that its 
aim was to clarify relevant policies for industry, develop internal procedures, and ensure 
effective communication between relevant centers. Furthermore, FDA aimed to promote 
consistent advice, efficient development, coordinated product review. 194 
The FDA noted its expectation that most therapeutic product and In Vitro Companion 
Diagnostic Devices (IVD) pairs will not meet the definition of combination product 
under 21CFR3.2(e). 195 This is because the FDA stated that it intends to require separate 
marketing applications for a therapeutic product and a companion diagnostic device, 
187 Id. 
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regardless of whether the products could constitute a combination product. 196 However, 
the FDA stated that the standards for review, approval or clearance would be the same. 197 
1. Timeline 
The FDA stated that ideally, a therapeutic product and its companion diagnostic will be 
developed and cleared contemporaneously. 198 However, the FDA recognized that there 
may be cases when contemporaneous development is not possible. 199 A companion 
diagnostic could be a new device, a new version of an existing device, or an existing 
device that has already been approved for another purpose.200 
2. Review And Approval 
In the guidance document, the FDA said that it reviews companion diagnostics and 
therapeutic products under applicable regulatory requirements.201 In other words, the 
FDA reviews companion diagnostics under the device authorities of the Federal Food, 
Drug, and Cosmetic (FD&C) Act, and therapeutic products under section 505 (drug 
products) of the FD&C Act or section 3 51 (biological products) of the Public Health 
Service Act.202 The FDA aims to review each companion diagnostic device application 
within the context of its corresponding therapeutic product.203 The FDC stated that 
when a new therapeutic product requires a companion diagnostic to be safe and effective 
use, the two products should be developed and approved contemporaneously.204 Before 
approving a therapeutic product, the FDA will make sure that the companion diagnostic 
device meets the applicable standard for safety and effectiveness.205 Furthermore, the 
FDA stated that it will generally not approve a therapeutic product if the companion 
diagnostic device is not approved or cleared for the same indication.206 
Later in the guidance, the FDA acknowledged that there are two situations where it 
may approve a therapeutic product even if its companion diagnostic device has not yet 
been approved.207 The FDA noted that in such situations, it expects that the companion 
diagnostic device will be subsequently approved.208 First, the FDA stated that it may 
approve a new therapeutic product intended to treat a serious or life-threatening 
condition for which no satisfactory alternative treatment exists, even if the therapeutic 
product's companion diagnostic has not been approved, if the FDA concludes that the 
196 ·see also 21 C.F.R. 3.4(c) (2015). 
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benefits outweigh the risks. 209 Second, the FDA might identify a serious safety issue 
and require revised labeling for an already approved therapeutic product, even if the 
companion diagnostic device has not yet been approved. 210 In this second scenario, 
the FDA will similarly compare the possible benefits of the therapeutic product against 
the possible risks of an unapproved companion diagnostic device.211 If the benefits 
outweigh the risks, the FDA will not delay approval of changes to the labeling of the 
therapeutic product until the companion diagnostic device is approved or cleared.212 The 
FDA emphasized that it generally will determine that a serious safety issue exists before 
approving a supplement to an approved therapeutic product application.213 In addition 
to the review and approval process, there are other policies that FDA and industry alike 
must keep in mind. 
3. General Policies 
If a therapeutic product requires the use of a companion diagnostic for its safe and 
effective use, an approved companion diagnostic should be available for use once the 
therapeutic product is approved.214 The FDA has stated that it will apply a risk-based 
approach to determine the regulatory pathway for companion diagnostic devices, as it 
does with all medical devices. 215 The regulatory pathway will depend on the level of risk 
to patients based on the intended use of the device and the controls necessary to assure 
safety and efficacy.216 Therefore, the level of risk will establish whether a companion 
diagnostic requires a PMA or a 510(k).217 
After completing review of the applications for a therapeutic product and a companion 
diagnostic, the FDA has stated its intention to issue approvals for both products at the 
same time.218 
If a diagnostic device is already legally marketed and its manufacturer intends to market 
its device for a new use as companion diagnostic with a therapeutic product, the FDA 
would likely consider this a new use for the device and would require an additional 
premarket submission.219 
New companion diagnostic devices intended to be used in the same manner as an 
existing approved companion diagnostic device will be reviewed under a PMA or a 
traditional 510(k) as appropriate.220 Although this guidance gives industry some insight 
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4. Unanswered Questions and Problems with the Guidance 
While the guidance document for companion diagnostics addressed many concerns 
regarding companion diagnostic products, there are still many critical gaps that make 
it difficult for products to enter the market. First, there are very different timelines 
associated with the development of drugs and biologics versus diagnostics, and the 
general concurrent approval requirement detailed in the guidance adds a significant 
amount of time required for the commercialization of products.221 Furthermore, the 
FDA stated in the guidance that it wants a companion diagnostic to be approved before 
the drug it is being paired with, but has stated that under some circumstances, it will 
allow a drug to be approved first. 222 While industry says that this apparent flexibility on 
the FDA's part can be helpful, it would be more effective and beneficial to have specific 
guidance on how to avoid a delayed companion diagnostic approval.223 
Second, if there are issues regarding the co-development of drugs and companion 
diagnostics, the FDA has simply offered to meet with the products' sponsors, but has 
not issued specific advice.224 While such a case-by-case analysis works now, as more 
companion diagnostic and therapeutic product pairs are developed, a case-by-case 
method may not be sustainable. Industry can benefit from further guidance specifically 
on co-development of drugs, biologics, and devices.225 This would allow companion 
diagnostics and their corresponding therapeutic products to be developed more quickly, 
which would benefit all stakeholders.226 
II. RECOMMENDATION 
Companion diagnostics bring up similar issues that combination products did before 
there was an OCP: Inter-center coordination, FDA and sponsor interaction, multiple 
marketing applications, disputes between centers and with sponsors, and long and 
delayed approval processes. 227 While OCP has not yet resolved certain issues, it has been 
tremendously helpful to the world of combination products.228 Therefore, the creation 
of an Office of Companion Diagnostics would similarly advance the development of 
those products. 
The Office of Companion Diagnostics can help with all of the issues that the FDA and 
industry struggled with before there was an Office of Combination Products.229 While 
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the FDA already has the expertise within its centers to help companion diagnostics and 
their corresponding therapeutic products be approved for the market, the FDA needs to 
centralize this expertise in an office where staff members can delegate responsibilities, 
help guide sponsors, keep track of where products are in the regulatory process, and 
help resolve disputes.230 An Office of Companion Diagnostics can help streamline 
the approval process for companion diagnostics, thereby encouraging innovation and 
furthering personalized medicine. 
A. Congress's Role 
For an Office of Companion Diagnostics to become a reality, Congress must take 
several steps. First, Congress must mandate that FDA create an Office of Companion 
Diagnostics through a statute that would amend the FDCA, similar to the MDUFMA 
establishing the OCP in 2002.231 This office should be authorized to set the standard of 
review for companion diagnostics and coordinate the various FDA centers reviewing 
marketing applications. Giving the Office of Companion Diagnostics this authority would 
encourage the efficient use of FDA resources, increase expertise within FDA's staff, 
and establish accountability for the agency's actions regarding marketing applications. 
Considering that an Office of Companion Diagnostics would be experimental, Congress 
should include a period of time to measure the success of the office. If at the end of this 
period, the office proves unsuccessful, the mandate should "sunset," eliminating the 
office. Congress should also review the office on an annual basis, just like it does with 
OCP.232 
Before an Office of Companion Diagnostics can be created, the Congressional Budget 
Office (CBO) will need to analyze how much money such an office would cost.233 The 
CBO report will likely include an estimate of how much the office will cost over a 
period of time, at which point provisions would sunset if unsuccessful.234 The CBO 
will recommend a certain amount of Congressional appropriations necessary for the 
office. 235 It is important to note that the Office of Companion Diagnostics will likely be 
more expensive in its first year than following years because more staff will be necessary 
for updating product tracking and establishing operating procedures for the office.236 
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1. User Fees 
The Office of Companion Diagnostics could be funded partially by appropriations 
from Congress and partially by fees paid by the products' sponsors.237 As industry will 
benefit from streamlined approval it is appropriate that they pay the normal user fees 
for their therapeutic products and the corresponding companion diagnostics, as well as 
an additional fee. These fees would fund the Office of Companion Diagnostics and go 
to processing the separate marketing applications for the therapeutic product and the 
companion diagnostic.238 Congress may anticipate that industry will not want to pay an 
additional user fee, and provide for various user fee waivers, like those available under 
MDUFMA and the Prescription Drug User Fee Act (PDUFA).239 
MDUFMA provides more limited user fee waiver options than PDUFA provides.240 
Under MDUFMA, almost every sponsor must pay the same standard fee upon submitting 
a device application.241 However, a small business, i.e., one whose annual gross sales and 
revenues is less than or equal to $30 million, follows a different fee structure.242 A small 
business pays 38% of the standard PMA and BLA fee and 80% of the standard 50l(k) 
fee. 243 MDUFMA also provides a one-time waiver for the first premarket application 
from a qualified small business.244 As MDUFMA applies to combination products, it 
would likewise apply to companion diagnostics.245 
PDUFA offers more options for user fee waivers.246 PDUFA offers a waiver for the 
first human drug application from a small business.247 However, PDUFA defines a 
small business differently than MDUFMA.248 Under PDUFA, a small business is one 
that has fewer than 500 employees for its business and affiliates. 249 PDUFA also offers 
waivers: 1) when necessary to protect the public health; 2) when the fee would present 
a significant barrier to innovation because of the applicant's limited resources or other 
circumstances; and 3) the fees would exceed the Secretary's anticipated present and 
future costs of reviewing the applicant's human drug applications.25° Furthermore, 
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PDUFA applications that do not require clinical data for approval only require half 
the fee that is necessary for applications that do require clinical data for approval.251 
Similarly, NDA or BLA supplements that require clinical data for approval are also 
assessed half the full application fee; whereas, NDA or BLA supplements that do not 
require clinical data are not assessed a fee. 252 
As companion diagnostics and their therapeutic products are becoming increasingly 
innovative and furthering personalized medicine, the PDUFA barrier to innovation 
waiver will likely apply to them. This waiver applies to innovative combination products 
for which two applications are appropriate.253 The FDA believes that "combination 
products may incorporate cutting edge, innovative technologies that hold great promise 
for advancing patient care."254 Furthermore, the FDA considers that combination 
products will make treatment safer or more effective. 255 This closely parallels companion 
diagnostics and their corresponding therapeutic products, which will personalize care for 
each patient.256 The FDA recognizes that the assessment of two marketing application 
fees for an innovative combination product could represent a significant barrier to its 
development. 257 The PDUFA barrier to innovation waiver allows the FDA to reduce the 
additional fee burden for innovative combination products when the person or company 
has limited resources.258 Similarly, companion diagnostics and their corresponding 
therapeutic products could benefit from the barrier to innovation waiver. 
The FDA cites several factors that it considers in determining product eligibility for an 
"Innovative Combination Product" waiver, which are likewise applicable to companion 
diagnostics. First, the product must address an unmet medical need in the treatment, 
diagnosis or prevention of disease.259 It can do this in areas where there is no approved 
alternative treatment or means of diagnosis, or if the companion diagnostic offers 
"significant, meaningful advantages" over existing approved alternative treatments.260 
Such advantages may include demonstrated superiority over existing treatments, ability 
to provide clinical benefit for those patients unable to tolerate current treatments, ability 
to provide clinical benefit without the serious side effects associated with current 
treatments, providing greater convenience or ease of use for patients and/or healthcare 
providers, improving safety by resulting in fewer adverse events, or improving 
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effectiveness by providing better patient compliance.261 Second, the FDA also considers 
if one of the two applications includes a new molecular entity, has been designated 
as a priority drug or is eligible for expedited device review, or has been granted fast 
track status. 262 The FDA notes that the existence of a treatment alternative would weigh 
against deciding that a product is innovative.263 
As the market for companion diagnostics is projected to grow at a substantial rate, 
sponsors face challenges. For instance, some therapeutic product sponsors may not 
have the expertise to develop a companion diagnostic. Independent developers may 
view companion diagnostics as a high-risk investment because its success would be 
linked to the regulatory approval of its corresponding therapeutic product.264 However, 
on the other hand, companion diagnostics may allow for optimal patient selection for 
a given therapeutic product which would increase the chances that an investigational 
product will show substantial evidence of safety and efficacy and make it more likely 
that the novel therapeutic will obtain FDA approval.265 Congress should consider these 
challenges and potential benefits, and create a special waiver for companion diagnostics 
like the Innovative Combination Product Waiver.266 This could reassure sponsors, 
encourage innovation, and result in specific, targeted therapies that can help a larger 
number of patients. 
2. Incentives 
Companion diagnostics not only pose great potential benefits for product sponsors, 
they also pose great risk in their investment. Companion diagnostics and their 
therapeutic products are dependent upon each other for approval and success, making 
the regulatory hurdles even greater.267 Considering these risks, manufacturers may not 
want to invest money into research and development for two products. However, the 
benefits of precision medicine for patients are great, and Congress should encourage 
innovation of companion diagnostics. One option is for Congress to extend the market 
exclusivity for drugs that rely on companion diagnostics. 268 Another option is to give 
companion diagnostics and their therapeutic products priority or accelerated review.269 
This paper will not go into the logistics of these options, but they are worthy of 
Congressional consideration. 
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B. Differences between OCD and OCP 
While the Office of Combination Products provides a template for an Office of 
Companion Diagnostics, companion diagnostics and their corresponding therapeutic 
products are different and will require a different process from combination products. 
First, an Office of Companion Diagnostics will need to issue a guidance document 
on substantive requirements for marketing authorization, which will help industry in 
their applications.270 The FDA will also likely need to pursue notice and comment 
rulemaking pursuant to the Administrative Procedure Act to avoid product sponsors 
alleging arbitrary and capricious action.271 
Second, experts from CBER or CDER and CDRH should meet to discuss the data that 
is submitted with each application for each product.272 As companion diagnostics will 
determine how best to administer their corresponding products, there will be some overlap 
of data submitted with their applications.273 Experts from the different FDA centers will 
need to discuss this overlap of data as well as issues of safety and efficacy that arise 
when the companion diagnostic is used with its therapeutic product.274 Additionally, 
unlike combination products, there will be no lead center for the approval process of 
the companion diagnostic and its therapeutic product. Thus, an Office of Companion 
Diagnostic should create an SOP to facilitate inter-center coordination, as companion 
products may require more coordination to streamline the regulatory process. 
Third, an Office of Companion Diagnostics will need to create an SOP to address what 
happens when a drug and device are not cleared contemporaneously. Currently, there is 
uncertainty about this, which needs to be addressed as manufacturers have marketing 
and business development concerns. 
Fourth, if a companion diagnostic might have a delayed approval, there needs to be an 
SOP that revises the regulatory timeline and notifies the product sponsor. 
Fifth, an Office of Companion Diagnostics would need to develop an SOP for sponsors to 
meet with FDA officials about the status of their applications. An established procedure 
for meeting with the FDA will ease product sponsors and increase transparency about 
the regulatory process. 
Sixth, an Office of Companion Diagnostics will need to develop a guidance discussing 
the necessity of cross-labeling products or providing mutually conforming labeling for 
products. 
Finally, an Office of Companion Diagnostics will need to address post-marketing issues. 
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notice and comment rulemaking, covering current Good Manufacturing Processes and 
Post Marketing Safety Regulations. 
1. Reality of Regulatory Process 
After reviewing the necessity of an Office of Companion Diagnostics and the steps 
required to create one, it's necessary to understand how this office would realistically 
operate. For instance, hypothetically, if Manufacturer X has developed drug Q and its 
companion diagnostic K, how would an Office of Companion Diagnostics help move Q 
and K through the regulatory process? 
In this hypothetical, X would submit applications to the Office of Companion Diagnostics 
for Q and K. The Office of Companion Diagnostics would do an initial review of the 
applications and create two tentative timelines for the regulatory process for Q and K. 
One timeline would be created for the product sponsors so they have notice of how long 
the process will take. As product sponsors will be paying user fees, a suggested timeline 
should be about six months. The second timeline would be a more detailed internal 
agency document that would be sent to the various involved FDA Centers and would 
contain estimated deadlines for each stage of the regulatory process. 
The Office of Companion Diagnostics would then assign the applications to specific 
experts within the Centers.275 The Office would create a schedule of meetings for 
the experts from the Centers to meet with each other to discuss overlapping data and 
whether clearance will be contemporaneous. The first meeting between experts of 
different Centers will occur after these experts have had time to do an initial review of 
the applications. 
For K, CDRH will apply a risk-based approach to determine the appropriate regulatory 
pathway, either a PMA or a 510(k). There are three risk classifications for medical 
devices (Class I, Class II, and Class III), which govern the level of FDA scrutiny 
necessary prior to marketing.276 Device classifications depend on the claimed intended 
use and the indications of the device.277 Class I devices are generally considered low 
risk, and are usually exempt from premarket clearance requirements such as submission 
of a 51 O(k) premarket notification. 278 Class II devices are considered to carry moderate 
risk and are reviewed for substantial equivalence to legally marketed products that have 
clearance for the same intended use by the premarket notification. 279 Class III devices are 
considered high-risk devices that are "life-saving" or "life-sustaining" and the majority 
of these devices require submission of a premarket approval application. 28° Companion 
diagnostics have been subject to Class III designations, and will likely continue to be.281 
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This is because they will be deemed as high-risk devices that will be used by health care 
professionals to determine if a patient should receive or discontinue a life-saving or life-
sustaining drug.282 Furthermore, most companion diagnostics will not have a predicate 
device to cite in a 510(k) submission.283 Notably, companion diagnostics approved 
through the PMA process may be eligible for a patent term extension.284 
For Q, CDER or CBER will review the two adequate and well-controlled clinical 
studies submitted with the application for safety and efficacy. CDER and CBER will 
also keep in mind whether the therapeutic product may be necessary to treat a serious 
or life-threatening condition where there is no satisfactory alternative treatment and the 
benefits outweigh the risk of not having the companion diagnostic.285 
Once the Centers have done an initial review, they will meet to determine how likely it 
would be for the companion diagnostic and its corresponding therapeutic product to be 
cleared contemporaneously.286 If the products will not be cleared contemporaneously, 
the Office of Companion Diagnostics will have an SOP for the product sponsors so 
the sponsors can address any marketing and business development concerns.287 This 
SOP should include a written explanation sent to product sponsors about why the 
products will not be cleared contemporaneously, an estimate as to when each product 
will be cleared, and an opportunity for the product sponsors to meet with the Office of 
Companion Diagnostics to address any concerns. 
After the experts from the Centers have met, they will continue with their normal 
individual review processes, and meet as necessary to address questions and concerns 
as they arise. Once the Centers have finished their reviews, they will meet one last time 
to finalize their decisions regarding approval and clearance, and then issue a written 
notification to the product sponsors. 
The Office of Companion Diagnostics will have an SOP for the product sponsors to 
meet in person to address any concerns or possibly appeal the decision. 
CONCLUSION 
While this paper does not address every necessary step and action to make an Office 
of Companion Diagnostics a reality, it adds to the growing debate and conversation. 
Personalized medicine is growing and is the future for the practice of medicine.288 
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they are becoming more and more intertwined. 289 As the field of companion diagnostics 
and corresponding therapeutic products grows, the FDA will need to adapt in order to 
maintain its regulatory authority. Furthermore, the creation of an Office of Companion 
Diagnostics will likely require a great deal of logistical planning, assistance from 
Congress, and a great deal of rule-making. However, it will be worth it because all 
stakeholders will benefit. Most importantly, patients will benefit, which is the ultimate 
goal. As President Obama said in his 2015 State of the Union, we can "lead a new era 
of medicine."290 
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